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Abstract 21 
Following a dramatic reduction in the cost of genotyping technology in recent years, there 22 
have been significant advances in the understanding of the genetic basis of glaucoma.  23 
Glaucoma patients represent around a quarter of all outpatient activity in the UK hospital eye 24 
service and are a huge burden for the National Health Service.  A potential benefit of genetic 25 
testing is personalised glaucoma management, allowing direction of our limited healthcare 26 
resources to the glaucoma patients who most need it.  Our review aims to summarise recent 27 
discoveries in the field of glaucoma genetics and to discuss their potential clinical utility.   28 
While genome-wide association studies have now identified over ten genes associated with 29 
primary open-angle glaucoma (POAG), individually, variants in these genes are not predictive 30 
of POAG in populations.  There are data suggesting some of these POAG variants are 31 
associated with conversion from ocular hypertension to POAG and visual field progression 32 
among POAG patients.  However, these studies have not been replicated yet and such genetic 33 
testing is not currently justified in clinical care.  In contrast, genetic testing for inherited early-34 
onset disease in relatives of POAG patients with a known genetic mutation is of clear benefit; 35 
this can support either regular review to commence early treatment when the disease 36 
develops, or discharge from ophthalmology services of relatives who do not carry the 37 
mutation.  Genetic testing for POAG at a population level is not currently justified. 38 
   39 
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Introduction 40 
Glaucoma remains the second commonest cause of certifiable visual loss in England and 41 
Wales.1  Given the chronic nature of glaucoma, lifelong follow-up is generally required.  42 
Therefore, glaucoma patients form a large proportion of outpatient activity in the UK hospital 43 
eye service (an estimated 23% of all follow-up attendances) with over 1 million glaucoma-44 
related visits per year.2,3  This represents a huge burden for the National Health Service (NHS) 45 
which is likely to grow further given the projected increase in the number of people with 46 
glaucoma.4  Genetic testing offers the promise of personalised glaucoma management and 47 
directing limited healthcare resources to the patients that need it most. 48 
There is strong evidence for a genetic contribution to the commonest form of glaucoma, 49 
primary open-angle glaucoma (POAG).  One twin study estimated the heritability of POAG to 50 
be 13%, though this is a likely underestimate given glaucoma case ascertainment was via 51 
prescribing registries and that a considerable proportion of glaucoma in a population is 52 
undiagnosed.5  First-degree relatives of POAG patients were shown to have a 9-fold increased 53 
risk of developing glaucoma in their lifetime compared to relatives of controls in the 54 
population-based Rotterdam Study.6  Most convincingly, with the advent of affordable high-55 
throughput DNA genotyping, there have now been multiple genes identified as contributing 56 
to susceptibility for POAG.7 57 
What is the future potential of genetic testing in the management of POAG?  For patients 58 
already diagnosed with POAG, genetic testing may offer prognostic information which may 59 
guide the intensity of their treatment and follow-up strategy.  Genetic testing may also guide 60 
which treatments are most suitable for individual patients, predicting the most efficacious 61 
treatment and the treatment least likely to induce side effects.  Within families with 62 
hereditary glaucoma, identifying the genetic cause will allow testing of offspring to determine 63 
who requires close monitoring and early treatment.  The potential benefits are clear to see, 64 
but is our knowledge sufficient or our tools accurate and affordable enough that we are now 65 
ready for genetic testing in glaucoma management?  Our review aims to answer these 66 
questions while giving a conceptual overview of POAG genetics and an update on recent 67 
advances in the field.  The role of genetic testing in congenital glaucomas8 is established and 68 
beyond the scope of this review. 69 
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 70 
Search strategy 71 
We conducted the following Medline search: "Genetic Testing"[Mesh] AND 72 
"Glaucoma"[Mesh].  We further considered studies that were referenced in the articles 73 
identified in the initial search. 74 
 75 
Mendelian versus complex disease 76 
Mendelian disorders are conceptually the simplest demonstration of how genes can be 77 
responsible for disease.  A single genetic defect alone causes a disease and if this is passed on 78 
by parents, their children will potentially inherit the disease.  Common forms of inheritance 79 
of Mendelian disorders include autosomal dominant, autosomal recessive and X-linked 80 
recessive.  If the genetic defect responsible for the disease in the family is identified, it is 81 
possible to screen offspring to determine their risk of disease and potentially take 82 
preventative action.  For example, Angelina Jolie famously underwent bilateral mastectomy 83 
to prevent breast cancer knowing she had inherited the BRCA1 gene mutation that had 84 
caused breast cancer in her family.9 85 
A complex disease is generally not caused by a single genetic defect; multiple genetic and/or 86 
environmental factors combine to collectively result in disease.  Conceptually, it can be 87 
considered that each individual risk factor is insufficient to cause disease on its own and that 88 
each risk factor may not be present in all cases of disease (Figure 1a).  The fact that the risk 89 
factor may not be present in all cases and yet present in some controls makes identifying each 90 
individual risk factor challenging in complex disease.  Large sample sizes are required to 91 
provide adequate power to identify each risk factor.  An alternative way of conceptualising 92 
complex disease is shown in Figure 1(b-d).  It may be that a single genetic factor is sufficient 93 
to cause disease, and that another single genetic factor is also sufficient to cause the disease, 94 
and these two different ‘flavours’ of the disease are indistinguishable or have not been 95 
separated during analyses.  Again, in this situation also, important risk factors may not be 96 
present in all cases of the disease, posing a challenge for their identification.  Similarly, large 97 
sample sizes can help identify each risk factor.  Additionally, in this conceptual model, 98 
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accurate phenotyping and separating cases into biologically meaningful subgroups can help 99 
improve power for detection of risk factors. 100 
 101 
Genetic mutations versus genetic variants 102 
As stated above, a Mendelian disease is caused by a single genetic alteration which is usually 103 
rare and is alone sufficient to cause a gene to malfunction and result in disease.  Such genetic 104 
alterations are termed ‘mutations’.  ‘Variants’, on the other hand, are points in the genome 105 
(DNA code) at which we vary from one another.  The human genome is greater than 3 billion 106 
nucleotides long, but we vary at less than 1% of these.  The commonest form of variation is a 107 
nucleotide substitution at a single point in the genome and this is referred to as a single 108 
nucleotide polymorphism (SNP).  A genetic variant alone does not cause disease, but may be 109 
associated with disease.  Possessing a variant may increase or decrease the risk of disease, 110 
but alone is insufficient to cause disease and is unlikely to be predictive of who will develop 111 
disease (cf arrows in Figure 1a).  Complex diseases may have many associated genetic 112 
variants.  It is the cumulative contribution of these associations, or potentially interactions 113 
between them, that ultimately result in disease (Figure 1a). 114 
 115 
Approaches to discovering genes that contribute to POAG  116 
Identifying a new gene for POAG in a hypothesis-independent manner requires methodology 117 
that looks for association across the whole genome.  Until recently, it was not feasible to 118 
examine all independently inherited SNPs genome-wide.  However, this was not necessary if 119 
examining genetic factors that segregate with disease in large families with inherited POAG.  120 
This approach is called linkage analysis and requires only around 400 markers to cover the 121 
whole genome.  Linkage studies have identified several genes associated with glaucoma, such 122 
as myocilin (MYOC),10 optineurin (OPTN)11 and WD repeat domain 36 (WDR36).12  Mutations 123 
in these genes have been reported to cause autosomal dominant Mendelian POAG in the 124 
studied families.  Further details on the roles of these genes in POAG have been previously 125 
reviewed.7,13,14  While a mutation in one of these genes may completely explain the 126 
development of POAG in some families, collectively, mutations in these genes contribute to 127 
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only around 6% of POAG cases in the general population.15–17  More recently, family studies 128 
have identified TANK binding kinase 1 (TBK1) as another cause of Mendelian POAG.18  Rather 129 
than a mutation within the gene, it is duplication of the gene and the resultant increase in 130 
function that appears to be causing the glaucomatous process. 131 
The cost of genome-wide genotyping has fallen dramatically in recent years, at a rate much 132 
faster than Moore’s Law.  This has resulted in affordable high-throughput technologies that 133 
can measure all common independently inherited genetic variation across the whole genome 134 
in individuals.  Therefore, it has become possible to investigate genetic associations with 135 
POAG, hypothesis independent and genome-wide, without the need for families.  Instead, 136 
unrelated POAG cases are collected and compared with unrelated controls at several million 137 
genetic markers (some directly measured and others imputed based on reference data).  This 138 
approach is called a genome-wide association study (GWAS).  GWAS identifies common 139 
variants (with a frequency of over 5% in the general population) associated with disease.  140 
Given the number of genetic variants examined, there is a multiple testing statistical issue.  141 
For this reason, associations are only considered significant and valid if the P-value is very 142 
small (a ‘hit’ is considered to be ‘genome-wide significant’ if P < 5x10-8) and there is evidence 143 
for the same association in an independent cohort.  The first glaucoma GWAS discovery was 144 
the LOXL1 locus for exfoliation glaucoma.19  The first replicated GWAS discovery for POAG 145 
was in an Icelandic population which identified a significant locus near CAV1 and CAV2 (both 146 
of which are expressed in retinal ganglion cells and trabecular meshwork).20  Further GWAS 147 
of European populations have identified other significant POAG loci in discovery cohorts from 148 
the United States21,22 (near or at SIX1/SIX6, TXNRD2, ATXN2 and FOXC1) and Australia23,24 149 
(TMCO1, CDKN2B-AS1, ABCA1, AFAP1 and GMDS).  A POAG GWAS in people of Chinese 150 
descent identified a significant locus in PMM2.25  Despite these identified variants being 151 
common, the effect of each one is small, and collectively they explain only a small fraction 152 
(<5%) of POAG heritability.  It is anticipated many more loci will be identified as the statistical 153 
power improves with a larger sample of POAG cases.  The first glaucoma GWAS success was 154 
for pseudoexfoliation glaucoma in 2007 which identified common variants in lysyl oxidase–155 
like protein 1 (LOXL1) as strongly associated with disease.19  Following this, the combination 156 
of cases from a large international consortium has identified further pseudoexfoliation 157 
glaucoma loci at CACNA1A,26 POMP, TMEM136, AGPAT1, RBMS3 and SEMA6A.27  There has also 158 
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been some GWAS success for primary angle-closure glaucoma, with eight genetic loci 159 
identified to date (near or at PLEKHA7, COL11A1, EPDR1, PCMTD1–ST18EPDR1, CHAT, GLIS3, 160 
FERMT2, and DPM2–FAM102A).28,29 161 
There have also been multiple GWAS hits for heritable quantitative traits related to glaucoma 162 
(endophenotypes), such as intraocular pressure (IOP), and optic cup-disc ratio (CDR).  A large 163 
IOP GWAS from the International Glaucoma Genetics Consortium (IGGC) identified GAS7 as a 164 
significant locus for both IOP and POAG.30  There have been over 40 genetic loci identified for 165 
CDR in the largest published GWAS meta-analysis from the IGGC.31  However, it remains 166 
unclear what role these loci have in disease, as the majority do not demonstrate association 167 
with POAG when tested in the available cohorts.  It is possible these variants are related to 168 
developmental processes and associated with optic disc anatomy and not the pathological 169 
glaucomatous cupping process.  Alternatively, these variants are associated with POAG 170 
aetiological processes, but there is insufficient power in the currently available POAG case-171 
control datasets to confirm the associations. 172 
 173 
Evidence for clinical utility of genetic testing in POAG 174 
Learning which genes contribute to POAG can inform us about previously unknown biological 175 
pathways that are important in disease aetiology and progression.  In the longer term, these 176 
discoveries can prompt further research into these pathways and potentially lead to new 177 
treatments.  In the shorter term, it is possible that genetic markers are of predictive value and 178 
can help personalise glaucoma management. 179 
 180 
Diagnosis in hereditary POAG 181 
There are situations when genetic testing can be helpful for managing families with inherited 182 
POAG.  For example, a young member of a family with severe, early onset, autosomal 183 
dominant POAG may benefit from knowing their likelihood of developing the disease.32  If the 184 
mutation causing POAG in that family is identified (e.g. by testing for myocilin mutations in 185 
affected family members), then the individual concerned can be tested for that mutation 186 
(cascade genetic testing).  If they do not carry the myocilin mutation, then their risk of 187 
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developing POAG will be similar to the risk in the general population, and this would allow 188 
discharge from routine ophthalmic examinations.32  Such information may even inform life 189 
choices such as occupation, especially if the disease is of early onset.  Conversely, if they do 190 
carry the mutation, this would warrant regular follow-up for early signs of raised IOP and 191 
permit early treatment. 192 
More general screening of relatives for an identified disease-causing mutation is termed 193 
cascade genetic testing.  There is some evidence that early diagnosis and treatment of 194 
myocilin-related POAG following cascade genetic testing may result in a better clinical 195 
outcome.  In a retrospective study, glaucoma severity parameters were compared between 196 
patients who were identified by cascade genetic testing (Genetic cases) and patients who 197 
presented through normal clinical pathways and were subsequently found to have a myocilin 198 
mutation (Clinical cases).33  Clinical cases had significantly higher maximum IOP, larger CDR 199 
and worse visual field mean deviation than Genetic cases.33 200 
It has been suggested there may be benefit in screening patients with advanced POAG for 201 
myocilin mutations if they meet certain criteria (young age of onset, high maximum IOP and 202 
strong family history).34  The prevalence of myocilin mutations in this phenotypically selected 203 
group ranged from 16% to 40% depending on the cut-off thresholds.  Identification of a 204 
myocilin mutation could then prompt cascade genetic testing and early treatment of family 205 
members at high risk.34 206 
Deciding whether to test patients or family members for myocilin mutations may not be 207 
straight-forward and genetic counselling should be offered.35  This may involve referral to a 208 
clinical genetics service.  Information provided should include details about the condition and 209 
its prognosis, its inheritance pattern, and risk to children or other family members.  210 
Counselling for at-risk but currently unaffected family members should explore the underlying 211 
motivation for genetic testing, and explain the testing process and potential impact of the 212 
test result.35  Accredited testing for myocilin mutations is currently available to NHS clinicians 213 
via the UK Genetic Testing Network.36  At the time of writing, sequencing the entire myocilin 214 
gene to look for any mutation cost £305, whereas testing for one known mutation in a family 215 
member cost £180.36  There is currently regional variation on whether commissioners will 216 
cover the cost of myocilin genetic testing. 217 
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 218 
Predicting conversion from ocular hypertension (OHT) to POAG 219 
A subset of participants of the Ocular Hypertension Treatment Study (OHTS) were genotyped 220 
for variants previously associated with POAG and these variants tested for association with 221 
subsequent conversion from OHT to POAG.37  Among the largest ethnic group in cohort, non-222 
Hispanic Whites, a SNP in TMCO1 was significantly associated with the development of POAG.  223 
TMCO1 has been strongly associated with IOP30,38 and it is assumed that the variant mediates 224 
its increased risk of POAG by raised IOP.  Remarkably, the association between the TMCO1 225 
variant and POAG conversion remained highly significant even after adjustment for all 226 
parameters in the previously published risk calculator,39 including baseline IOP; the hazard 227 
ratio was 1.7 per risk allele (95% confidence interval 1.3 – 2.3, P = 0.0004).37  This equates to 228 
a 3-fold increased risk of POAG in people with two risk alleles compared to people with no 229 
risk alleles, an effect size that is comparable to other established risk factors such as age.  It 230 
is perhaps surprising that the TMCO1 effect remains significant even after adjustment for a 231 
direct measurement of IOP.  This suggests that the TMCO1 variant provides information 232 
regarding the cumulative level of true IOP over and above that provided by a single 233 
measurement at baseline.  While this is an exciting finding that offers hope for the potential 234 
of genetic testing in the management of OHT, replication of this finding in an independent 235 
study would provide stronger evidence.  It should also be noted that there was no discernible 236 
association between the TMCO1 variant and conversion to POAG in the Black subgroup.37  237 
 238 
Predicting progression of POAG 239 
Examining risk factors for susceptibility to progression of POAG in treated cohorts is 240 
challenging, not least because intensity of treatment is difficult to quantify and account for.  241 
A study of 469 Singaporean Chinese POAG patients with 5 or more visual fields showed that 242 
only one of ten POAG loci tested was associated with visual field progression (ascertained by 243 
pointwise linear regression criteria).40  This locus was in the TGFBR3-CDC7 region and was 244 
associated with a 6.7 (95% CI 1.9 - 23.7, P = 0.003) times increased chance of visual field 245 
progression.  The wide confidence interval suggests uncertainty of this effect estimate and 246 
there is a possibility this is a chance finding.  Replication in an independent cohort is required 247 
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before firm conclusions can be made.  Unfortunately, data for the TMCO1 variant that was 248 
examined in OHTS were not available for this study. 249 
 250 
Predicting response to treatment 251 
There is good evidence that, in general, there may be a genetic basis for effectiveness of 252 
treatment in different individuals, as well as for the development of side effects for 253 
treatment.41  However, pharmacogenomic studies for glaucoma treatments have been small 254 
and with conflicting results.  For example, variants in the prostaglandin F2α gene have been 255 
associated with response to prostaglandin analogues in Japanese studies42,43 but not in a 256 
North American study.44  A variant in ADRB2 has been associated with response to timolol 257 
drops, but this finding remains unreplicated.45  Currently, there is no convincing evidence for 258 
genetic testing to support the choice of treatment for POAG. 259 
 260 
Targeted therapy for Mendelian POAG 261 
Identifying the disease-causing mutation in Mendelian POAG offers the potential for targeted 262 
therapy to fix the specific molecular defect caused by the mutation.  It has been suggested 263 
that myocilin mutations result in misfolded MYOC protein accumulating in trabecular 264 
meshwork cells resulting in an adverse effect.46  Phenylbutyrate, a chemical chaperone that 265 
aids proteins folding into their correct conformations, appears to cure myocilin-caused 266 
glaucoma in transgenic mice when administered orally or as an eyedrop.46,47  While 267 
phenylbutyrate has not been tested in humans, this may serve as a proof of concept for 268 
targeting treatment to the underlying pathology caused by a specific genetic defect. 269 
More recently, clustered regularly interspaced short palindromic repeats (CRISPR)-mediated 270 
genome editing was used to disrupt the mutant myocilin gene in a mouse model, resulting in 271 
reduced endoplasmic reticulum stress, lower IOP, and prevention of further glaucomatous 272 
damage.48  Additionally, the investigators demonstrated the potential feasibility of human 273 
genome editing in the eye using an ex vivo human organ culture system.48 274 
 275 
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Conclusions 276 
The pace of new genetic discoveries for glaucoma has increased significantly in recent years 277 
due to the exponential drop in cost of high-throughput genome-wide genotyping platforms.  278 
While there is some evidence supporting the clinical utility of this new knowledge, such as 279 
TMCO1 variation being predictive of conversion from OHT to POAG, such studies are small 280 
and not replicated to date.  Genetic testing for glaucoma is clearly helpful in some specific 281 
situations, such as screening of family members in autosomal dominant POAG of early onset.  282 
POAG pharmacogenomics is an understudied area that warrants further work in the GWAS-283 
era.  However, genetic testing for POAG at a population level is not currently justified.  We 284 
look forward to further genetic discoveries for glaucoma as statistical power increases, from 285 
large cohorts such as the UK Biobank and from global collaborations such as the IGGC.  Time 286 
will tell if these discoveries will help us manage our patients better, or at least help direct 287 
resources to those who need them most. 288 
  289 
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Figure 1:  Conceptual diagrams for complex disease.  Each circle represents an individual 431 
person; filled in circles are people affected by disease and hollow circles are unaffected 432 
controls.  1(a) and 1(b/c/d) are two different concepts for complex disease. 433 
First concept: 1(a) - The arrows are risk factors (genetic or environmental); different colours 434 
represent different risk factors.  It can be seen that none of the risk factors are present in all 435 
of the cases, and some of the risk factors that contribute to disease are present in controls. 436 
Second concept: 1(b) – In this concept, each individual risk factor is sufficient to cause the 437 
disease.  The different colours represent different subsets of disease which may or may not 438 
be clinically distinguishable.  1(c) – If all cases are examined together, identifying each risk 439 
factor can be challenging as they are present only in subset of cases.  1(d) – If the cases are 440 
subdivided in a biologically meaningful way, this can increase the power to identify risk factors 441 
despite the smaller sample size. 442 
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